News by subject: Clinical Study

First in human clinical study provides proof-of-concept for mitochondrial augmentation therapy platform, which enables use of healthy mitochondria to improve mitochondrial function and mitigate effects of large-scale mitochondrial DNA (mtDNA)...

XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the completion of dosing in the XRX-OXY-101...

Small Pharma Inc. (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today confirms that the first patient has been dosed in the Company's Phase Ib drug...

Avicanna Inc. ("Avicanna" or the "Company") , a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it will be initiating an...

ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 (UM171-expanded) Cell Therapy...

Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety and Efficacy Profile may Position Drug to Become the Preferred Kinase Inhibitor for Triplet...

Biogen Inc. ? announced that the U.S. Food and Drug Administration (FDA) has accepted for review the abbreviated Biologics License Application (aBLA) for BIIB800, a biosimilar candidate referencing ACTEMRA®1 (tocilizumab), an anti-interleukin-6...

Sirona Biochem Corp. ("Sirona") is pleased to announce that the clinical trial, for novel anti-aging compound TFC-1326, started on December 5th, 2022. The trial, which will take place in Paris, is designed to assess the compound's efficacy in...

Lucira COVID-19 & Flu Test is the first and only combination over-the-counter self-test with fast, molecular lab-quality results enabling mass testing of symptomatic residents, staff and visitors amid the aggressive COVID-19 and flu season in...

Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its...

Providence Therapeutics Holdings Inc. ("Providence") today announced that Aleksandra Pastrak, M.D., Ph.D., chief medical officer of Providence Therapeutics, will deliver a...

AXS-05 statistically significantly delayed time to relapse of Alzheimer's disease agitation versus placebo (p=0.014, primary endpoint) AXS-05 statistically significantly prevented relapse of Alzheimer's disease agitation versus placebo (p=0.018,...

Evaxion Biotech A/S ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced promising clinical data from the Phase 1/2a first-in-human study of its DNA-based...

Sirona Biochem Corp. ("Sirona") is pleased to announce positive results of the clinical safety study for their novel anti-aging compound TFC-1326 1% in formulation, now proven to be a non-irritant and non-sensitizer. TFC-1326, Sirona's lead...

Sunshine Biopharma Inc. , a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals today announced that it has entered into a collaboration agreement with one of...

InMed Pharmaceuticals Inc. ("InMed" or the "Company") , a leader in the pharmaceutical research, development and manufacturing of rare...

Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") , a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has commenced screening subjects for its Phase 1 clinical study of an intravenous formulation...

Organovo Holdings, Inc. , a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announced that it has successfully advanced the use of its...

Dr. Pierre Debs, Ph.D. announced today the launch of Chain Pharmaceuticals GmbH, a phytocannabinoid drug discovery company leveraging machine learning and real world medical data in the development of clinically proven plant-based medicines for...

Aptose Biosciences Inc. ("Aptose") , a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced dosing of the first patient to receive a continuous dosing regimen of the G3...

Medicenna Therapeutics Corp. ("Medicenna" or "the Company") , a clinical stage immunotherapy company, today...

Evaxion Biotech A/S ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that it intends to further increase its focus on its lead oncology assets EVX-01...

HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in combination with an RNAi, may provide enhanced HBV...

Small Pharma Inc. (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has received...

Covis Pharma Group ("Covis"), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses, today announced positive topline results from the AVANT phase 3 clinical...

Bright Peak Therapeutics, a privately held biotechnology company developing...

Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has finalized an amended protocol to the...

IntelGenx Corp.  (the "Company" or "IntelGenx") today provided an update on its collaboration with its strategic partner, atai Life Sciences ("atai"), for the development of novel formulations of pharmaceutical-grade psychedelics based on...

Findings from this collaborative project with the University of Alberta using a unique surgical methodology illustrate how PGX-processed carriers can successfully be uniformly loaded with a fat-soluble active ingredient to generate superior bioactive...

Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. ("Coherus") today announced the publication of toripalimab plus chemotherapy for patients with treatment-naïve advanced non-small cell...

ChristianaCare, a leading non-profit health system in the mid-Atlantic region, today announced it has spun out its first commercial biotechnology private start-up company, named CorriXR Therapeutics. CorriXR Therapeutics (pronounced Cor-ix-er; from...

Mindset Pharma Inc. ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs,...

Spectral Medical Inc. ("Spectral" or the "Company") , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market...

Kane Biotech Inc. (the "Company" or "Kane Biotech") today announces that it has received an additional $425,000 USD of funding for its DispersinB Hydrogel® related to its Medical Technology Enterprise Consortium Research Project Award which was...

Axsome Therapeutics,...

Resverlogix Corp. ("Resverlogix" or the "Company") today announced that apabetalone's future clinical development related to COVID-19 will focus on the prevention and treatment of Post COVID-19 Conditions (PCC), colloquially known as long-COVID, as...

Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform designed to restore innate immune function, is pleased to announce it has received Health Canada clearance...

Biogen Inc. today announced that The...

Small Pharma Inc. (the "Company" or "Small Pharma"), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has completed enrollment in the Phase IIa clinical trial of...

Psyence Group Inc.  ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is delighted to announce that it has received approval for its Phase IIa clinical trial...

Ketamine was safe, well-tolerated with 100% of patients treated with ketamine demonstrating reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS) UDysRS showed a 51% reduction from baseline during Infusion 2 (p=0.003),...

Novan, Inc. ("the Company" or "Novan") , today announced that EPI Health, a Novan Company, and MC2 Therapeutics presented data from a previously unpublished subgroup analysis of the U.S. Phase 3 pivotal...

Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has filed an amended protocol to the U.S....

Acasti Pharma Inc. ("Acasti" or the "Company") , today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the comparative bioavailability, pharmacokinetics, and safety of its oral betamethasone spray, GTX-102,...

Rubius Therapeutics, Inc. , a biopharmaceutical company that...

Healthcare professionals, social workers and counsellors working in the substance use field are experiencing higher levels of burnout. A new study released today by the Canadian Centre on Substance Use and Addiction (CCSA) says the drug toxicity...

Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that it has enrolled the first patient in the ADVANCE-2 trial of AXS-05, an...

The completion of the ISA's review of the Collector Test Environmental Impact Statement (EIS) paves the way for TMC subsidiary, Nauru Ocean Resources Inc (NORI), to conduct its planned pilot collection system trials on its NORI-D exploration area in...

Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the publication of a post-hoc analysis comparing the effects of Sunosi®...

KETARXtm Ketamine Patch demonstrated extended delivery of ketamine over 40 hours KETARXtm Ketamine Patch offers flexible dosing through increased size, drug load or concentration of ketamine to better align with intramuscular and intravenous...